Administer barbiturates with caution in sufferers with hepatic destruction and at decreased doses at first; barbiturates shouldn't be administered to clients demonstrating the premonitory signs of hepatic comapentobarbital will decrease the extent or influence of rolapitant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use